Plain-English translation of NCT01999361 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes Mellitus research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a medication called can help prevent your immune system from becoming sensitized—or overly reactive—after an islet transplant stops working. People who have received islet transplants and experienced complete graft loss will take this medication alone for two years, then gradually stop it while doctors monitor whether sensitization develops.
When an islet transplant fails completely, doctors don't fully understand the best way to protect patients from developing strong immune reactions that could make future transplants harder to match. This study is designed to find out if this medication can prevent that immune sensitization from happening in the first place.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would take as your only immunosuppressive medication for 2 years after your islet transplant completely stops working. After those 2 years, you would gradually stop taking the medication while continuing to visit the clinic for blood tests to check whether your immune system has developed sensitization. The entire study lasts about 3 years, with regular monitoring to make sure you stay healthy.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States
Sponsor
Rodolfo Alejandro
Enrollment target
~18 participants
Started
January 2009
Primary completion
January 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.